Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINIVELLE vs EVAMIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and regulation of target tissues including reproductive, cardiovascular, skeletal, and CNS systems.
Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (use for >5 years only if clearly needed)
Treatment of moderate to severe vasomotor symptoms due to menopause,Off-label: Prevention of postmenopausal osteoporosis (not FDA-approved for this indication)
Transdermal: Apply 0.025-0.1 mg/day patch twice weekly (every 3-4 days).
1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.
Terminal half-life: 12-18 hours for estradiol; clinical context: once-daily or twice-weekly dosing maintains steady-state concentrations.
Terminal elimination half-life is 4 hours; clinical context: dosing every 6-8 hours maintains therapeutic levels
Primarily hepatic metabolism via CYP3A4 to estrone and estriol, followed by conjugation (glucuronidation, sulfation).
Estradiol is primarily metabolized in the liver via CYP3A4 and other cytochrome P450 enzymes. It is also metabolized in the gastrointestinal tract and skin. Major metabolites include estrone and estriol, which are conjugated (sulfates and glucuronides) and excreted in urine.
Renal: 80-90% as glucuronide and sulfate conjugates; Fecal: 10-20% via bile; <1% unchanged.
Renal (90%) as metabolites; fecal (<5%); biliary (<1%)
98% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
80% bound to albumin and alpha-1-acid glycoprotein
Approximately 1.2-1.5 L/kg; extensive distribution into tissues.
3-5 L/kg; indicates extensive tissue distribution
Transdermal: approximately 82% of dose absorbed (avoid first-pass metabolism); oral: <5% due to extensive hepatic first-pass.
Intranasal: 70%; oral: not applicable (first-pass metabolism)
No specific dosage adjustment recommended; use with caution in severe impairment.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use lowest effective dose.
Contraindicated in Child-Pugh Class B and C (moderate to severe hepatic impairment). No data for mild impairment; use with caution.
Safety and efficacy not established; not FDA-approved for pediatric use.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Use lowest effective dose; monitor for thromboembolic events and malignancy; consider shorter duration.
No specific dose adjustment recommended; however, initiate at lowest effective dose due to increased risk of adverse effects (e.g., thromboembolism, malignancy) in elderly.
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Use progestin when uterus is present. Do not use for prevention of cardiovascular disease or dementia. Increased risk of probable dementia in women ≥65 years. Increased risk of breast cancer, stroke, DVT, and pulmonary embolism.
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Use of unopposed estrogens is associated with an increased risk of endometrial hyperplasia and carcinoma. Additionally, estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) study reported increased risks of stroke, deep vein thrombosis, pulmonary embolism, and breast cancer with estrogen-alone therapy.
Cardiovascular disorders (stroke, MI, DVT), malignant neoplasms (endometrial, breast, ovarian), dementia, gallbladder disease, hypercalcemia, visual abnormalities, hereditary angioedema, exacerbation of endometriosis, and fluid retention. Minimize dose and duration.
Risk of endometrial cancer: Use progestin in women with intact uterus.,Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, especially in smokers and older women.,Breast cancer: Increased risk with long-term use.,Dementia: Increased risk in women ≥65 years old.,Gallbladder disease.,Hypercalcemia in patients with breast cancer and bone metastases.,Retinal vascular thrombosis: Discontinue if sudden vision loss occurs.,Fluid retention: Use with caution in patients with conditions exacerbated by edema.,Hypothyroidism: May need increased thyroid replacement dose.,Hepatic impairment: Contraindicated in severe liver disease.
Undiagnosed abnormal genital bleeding, known/suspected breast cancer (except certain metastatic cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history thereof, active arterial thromboembolic disease (e.g., stroke, MI), known protein C/protein S/antithrombin deficiency, liver impairment or disease, known pregnancy, hypersensitivity to estradiol or components.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-sensitive neoplasia,Active or history of deep vein thrombosis or pulmonary embolism,Active or history of arterial thromboembolic disease (e.g., stroke, MI),Known thrombophilic disorders (e.g., Protein C, S, or antithrombin deficiency),Hepatic impairment or disease,Pregnancy,Hypersensitivity to estradiol or any ingredient
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism and increase estradiol levels. St. John's wort may induce estrogen metabolism and reduce efficacy. No significant interactions with other foods.
Grapefruit and grapefruit juice may increase estradiol levels; avoid excessive consumption. No other significant food interactions reported.
Estrogens, including estradiol (MINIVELLE), are contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, particularly cardiovascular and urogenital defects. Second and third trimester exposure may increase risk of fetal reproductive tract abnormalities, including vaginal adenosis and clear cell adenocarcinoma in female offspring. Estrogens should not be used during pregnancy.
Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and potential long-term reproductive tract effects in offspring. Use is not recommended at any gestational stage.
Estradiol is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. Infant exposure is considered low, but estrogens may reduce milk production and composition. Use during breastfeeding is generally not recommended, especially in the early postpartum period. Consider alternatives.
Estradiol is excreted in breast milk. The milk-to-plasma ratio is approximately 0.1-0.2. Studies show low concentrations in milk, but long-term effects on the infant are unknown. Evamist is not recommended during breastfeeding due to potential hormonal disruption and reduced milk production.
Estrogen metabolism is altered in pregnancy due to increased hepatic clearance and plasma volume. However, MINIVELLE is contraindicated in pregnancy; therefore, no dose adjustment recommendations are provided. Use is not advised under any circumstances.
No dosing adjustments applicable as Evamist is contraindicated in pregnancy. In the non-pregnant state, no dosage adjustment is needed. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) are not relevant as the drug should not be used.
Minivelle (estradiol transdermal system) delivers continuous estradiol for hormone therapy. Apply to clean, dry, intact skin on lower abdomen or upper buttock; avoid breasts and waistline. Rotate application sites with at least 1-week interval. Do not apply to oily, irritated, or sunburned skin. If patch falls off, reapply or replace with a new patch; maintain same schedule. Monitor for signs of thromboembolism, stroke, or breast cancer. Discontinue if migraine develops. Use lowest effective dose for shortest duration.
Apply EVAMIST to clean, dry, intact skin of the axilla or inner thigh. Avoid application to irritated or broken skin. Rotate application sites to minimize local skin reactions. Do not apply to the breast or vaginal area. For optimal absorption, wait at least 1 hour after application before showering or swimming. Monitor serum estradiol levels if inadequate symptom relief or adverse effects occur.
Apply patch once weekly on the same day.,Choose a clean, dry area on your lower belly or upper buttock; never place on breasts.,Rotate application sites; do not use the same spot twice within 1 week.,If patch falls off, reapply a new one; if it has been off for more than 8 hours, apply a new patch and note the day.,Do not expose patch to direct heat sources (heating pads, saunas, sunbathing) as it may increase drug absorption.,Report any sudden severe headache, vision changes, chest pain, shortness of breath, or leg swelling/pain.,Avoid grapefruit juice and St. John's wort, as they may alter drug effectiveness.,Do not smoke while using this medication; smoking increases risk of blood clots and heart disease.
Apply the gel to clean, dry skin on your armpit or inner thigh.,Rotate application sites daily to avoid skin irritation.,Avoid applying to the breast or vaginal area.,Do not wash the application area for at least 1 hour after applying.,Keep away from children and pets; wash hands thoroughly after application.,Do not use if you are pregnant, breastfeeding, or have a history of certain cancers.,Report any unusual vaginal bleeding, breast lumps, or signs of blood clots immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINIVELLE vs EVAMIST, answered by our medical review team.
MINIVELLE is a Estrogen Replacement that works by Estradiol binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and regulation of target tissues including reproductive, cardiovascular, skeletal, and CNS systems.. EVAMIST is a Estrogen Replacement that works by Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINIVELLE and EVAMIST depend on the specific clinical indication. These are both Estrogen Replacement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINIVELLE is: Transdermal: Apply 0.025-0.1 mg/day patch twice weekly (every 3-4 days).. The standard adult dose of EVAMIST is: 1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINIVELLE and EVAMIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINIVELLE is classified as Category C. Estrogens, including estradiol (MINIVELLE), are contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, particularly cardiovascula. EVAMIST is classified as Category C. Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. S. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.